EP1395276A4 - Structurally modified peptides and uses thereof - Google Patents

Structurally modified peptides and uses thereof

Info

Publication number
EP1395276A4
EP1395276A4 EP02731790A EP02731790A EP1395276A4 EP 1395276 A4 EP1395276 A4 EP 1395276A4 EP 02731790 A EP02731790 A EP 02731790A EP 02731790 A EP02731790 A EP 02731790A EP 1395276 A4 EP1395276 A4 EP 1395276A4
Authority
EP
European Patent Office
Prior art keywords
modified peptides
structurally modified
structurally
peptides
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02731790A
Other languages
German (de)
French (fr)
Other versions
EP1395276A1 (en
Inventor
Jean E Gairin
Jean-Sebastien Blachet
I Dufau
C Nguyen
B Monsarrat
Danila Valmori
Pedro Romero
Jean-Charles Cerottini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Centre National de la Recherche Scientifique CNRS
Ludwig Institute for Cancer Research New York
Original Assignee
Ludwig Institute for Cancer Research Ltd
Centre National de la Recherche Scientifique CNRS
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Centre National de la Recherche Scientifique CNRS, Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research Ltd
Publication of EP1395276A1 publication Critical patent/EP1395276A1/en
Publication of EP1395276A4 publication Critical patent/EP1395276A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
EP02731790A 2001-05-15 2002-05-14 Structurally modified peptides and uses thereof Withdrawn EP1395276A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29064601P 2001-05-15 2001-05-15
US290646P 2001-05-15
PCT/US2002/015217 WO2002092120A1 (en) 2001-05-15 2002-05-14 Structurally modified peptides and uses thereof

Publications (2)

Publication Number Publication Date
EP1395276A1 EP1395276A1 (en) 2004-03-10
EP1395276A4 true EP1395276A4 (en) 2004-12-29

Family

ID=23116948

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02731790A Withdrawn EP1395276A4 (en) 2001-05-15 2002-05-14 Structurally modified peptides and uses thereof

Country Status (2)

Country Link
EP (1) EP1395276A4 (en)
WO (1) WO2002092120A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002951212A0 (en) * 2002-09-04 2002-09-19 Monash University A method of modulating cellular activity and molecules for use therein
WO2011140284A2 (en) 2010-05-04 2011-11-10 Fred Hutchinson Cancer Research Center Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033511A1 (en) * 1997-02-05 1998-08-06 Ludwig Institute For Cancer Research Structurally modified peptides resistant to peptidase degradation
WO2001070772A2 (en) * 2000-03-23 2001-09-27 Pierre Fabre Medicament Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of an addition salt to an acid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
DK0735893T3 (en) * 1993-09-14 2009-03-09 Pharmexa Inc PAN DR-binding peptides to enhance the immune response
US6218363B1 (en) * 1996-08-28 2001-04-17 Thomas Jefferson University MHC peptides and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033511A1 (en) * 1997-02-05 1998-08-06 Ludwig Institute For Cancer Research Structurally modified peptides resistant to peptidase degradation
WO2001070772A2 (en) * 2000-03-23 2001-09-27 Pierre Fabre Medicament Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of an addition salt to an acid

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AYYOUB MAHA ET AL: "Analysis of the degradation mechanisms of MHC class I-presented tumor antigenic peptides by high performance liquid chromatography/electrospray ionization mass spectrometry: Application to the design of peptidase-resistant analogs", RAPID COMMUNICATIONS IN MASS SPECTROMETRY, vol. 12, no. 9, 1998, pages 557 - 564, XP008037828, ISSN: 0951-4198 *
BECK A ET AL: "Stability and CTL activity of N-terminal glutamic acid containing peptides.", THE JOURNAL OF PEPTIDE RESEARCH : OFFICIAL JOURNAL OF THE AMERICAN PEPTIDE SOCIETY. JUN 2001, vol. 57, no. 6, June 2001 (2001-06-01), pages 528 - 538, XP002303302, ISSN: 1397-002X *
BIANCO A ET AL: "N-Hydroxy-amide analogues of MHC-class I peptide ligands with nanomolar binding affinities.", JOURNAL OF PEPTIDE SCIENCE : AN OFFICIAL PUBLICATION OF THE EUROPEAN PEPTIDE SOCIETY. DEC 1998, vol. 4, no. 8, December 1998 (1998-12-01), pages 471 - 478, XP008037890, ISSN: 1075-2617 *
BLANCHET J S ET AL: "A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implication for molecular anti-melanoma immunotherapy.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 NOV 2001, vol. 167, no. 10, 15 November 2001 (2001-11-15), pages 5852 - 5861, XP002303301, ISSN: 0022-1767 *
BRINCKERHOFF L H ET AL: "Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER. 29 OCT 1999, vol. 83, no. 3, 29 October 1999 (1999-10-29), pages 326 - 334, XP002303298, ISSN: 0020-7136 *
GUICHARD G ET AL: "Melanoma peptide MART-1(27-35) analogues with enhanced binding capacity to the human class I histocompatibility molecule HLA-A2 by introduction of a beta-amino acid residue: implications for recognition by tumor-infiltrating lymphocytes.", JOURNAL OF MEDICINAL CHEMISTRY. 5 OCT 2000, vol. 43, no. 20, 5 October 2000 (2000-10-05), pages 3803 - 3808, XP002303299, ISSN: 0022-2623 *
QUESNEL A ET AL: "Synthesis and antigenic properties of reduced peptide bond analogues of an immunodominant epitope of the melanoma MART-1 protein.", JOURNAL OF PEPTIDE SCIENCE : AN OFFICIAL PUBLICATION OF THE EUROPEAN PEPTIDE SOCIETY. MAR 2001, vol. 7, no. 3, March 2001 (2001-03-01), pages 157 - 165, XP008037820, ISSN: 1075-2617 *
See also references of WO02092120A1 *
VALMORI D ET AL: "ENHANCED GENERATION OF SPECIFIC TUMOR-REACTIVE CTL IN VITRO BY SELECTED MELAN-A/MART-1 IMMUNODOMINANT PEPTIDE ANALOGUES", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 160, no. 4, 1998, pages 1750 - 1758, XP000887160, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
EP1395276A1 (en) 2004-03-10
WO2002092120A1 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
EP1463742A4 (en) Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
EP1390393A4 (en) Pentapeptide compounds and uses related thereto
HUP0500992A2 (en) Tacis and br3 polypeptides and uses thereof
HUP0500989A2 (en) Animicrobial polypeptides and their uses
EP1408978A4 (en) Novel phenylamino-pyrimidines and uses thereof
PT1390516E (en) Novel expression vectors and uses thereof
IL154553A0 (en) Urocortin-iii and uses thereof
EP1419175A4 (en) Replikin peptides and uses thereof
EP1414848A4 (en) Replikin peptides and uses thereof
EP1462455A4 (en) Novel peptides and medicinal uses thereof
IL131707A0 (en) Acetylcholinesterase-derived peptides and uses thereof
GB0100196D0 (en) Peptides
EP1408985A4 (en) Novel pyridopyrimidones and uses thereof
HK1063486A1 (en) Novel expression vectors and uses thereof
GB0026134D0 (en) Peptides and their use
GB0109438D0 (en) Peptides
EP1395276A4 (en) Structurally modified peptides and uses thereof
EP1367123A4 (en) Neurotonin and use thereof
SG10201403662QA (en) Replikin peptides and uses thereof
GB0108752D0 (en) Peptide epitopes and uses thereof
GB0102447D0 (en) Protein variants and uses thereof
IL158109A0 (en) Replikin peptides and uses thereof
IL159495A0 (en) Replikin peptides and uses thereof
AUPR589701A0 (en) Novel peptide and use thereof
IL149179A0 (en) FcyRII-BINDING PEPTIDES AND USES THEREOF

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 38/17 B

Ipc: 7C 07K 14/47 A

A4 Supplementary search report drawn up and despatched

Effective date: 20041116

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050203